Protalix Biotherapeutics Stock Performance
| PLX Stock | USD 1.79 0.05 2.87% |
The company holds a Beta of 0.99, which implies possible diversification benefits within a given portfolio. Protalix Biotherapeutics returns are very sensitive to returns on the market. As the market goes up or down, Protalix Biotherapeutics is expected to follow. At this point, Protalix Biotherapeutics has a negative expected return of -0.41%. Please make sure to check Protalix Biotherapeutics' treynor ratio, accumulation distribution, as well as the relationship between the Accumulation Distribution and period momentum indicator , to decide if Protalix Biotherapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Protalix Biotherapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's essential indicators remain fairly strong which may send shares a bit higher in February 2026. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
| Begin Period Cash Flow | 23.6 M | |
| Total Cashflows From Investing Activities | 4.2 M |
Protalix Biotherapeutics Relative Risk vs. Return Landscape
If you would invest 250.00 in Protalix Biotherapeutics on October 7, 2025 and sell it today you would lose (71.00) from holding Protalix Biotherapeutics or give up 28.4% of portfolio value over 90 days. Protalix Biotherapeutics is generating negative expected returns assuming volatility of 4.6922% on return distribution over 90 days investment horizon. In other words, 42% of stocks are less volatile than Protalix, and above 99% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
Protalix Biotherapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Protalix Biotherapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Protalix Biotherapeutics, and traders can use it to determine the average amount a Protalix Biotherapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0883
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | PLX |
Based on monthly moving average Protalix Biotherapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Protalix Biotherapeutics by adding Protalix Biotherapeutics to a well-diversified portfolio.
Protalix Biotherapeutics Fundamentals Growth
Protalix Stock prices reflect investors' perceptions of the future prospects and financial health of Protalix Biotherapeutics, and Protalix Biotherapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Protalix Stock performance.
| Return On Equity | 0.13 | ||||
| Return On Asset | 0.0553 | ||||
| Profit Margin | 0.09 % | ||||
| Operating Margin | 0.12 % | ||||
| Current Valuation | 118.74 M | ||||
| Shares Outstanding | 80.42 M | ||||
| Price To Earning | (1.23) X | ||||
| Price To Book | 2.64 X | ||||
| Price To Sales | 2.26 X | ||||
| Revenue | 53.4 M | ||||
| EBITDA | 6.52 M | ||||
| Cash And Equivalents | 19.76 M | ||||
| Cash Per Share | 0.41 X | ||||
| Total Debt | 5.53 M | ||||
| Book Value Per Share | 0.66 X | ||||
| Cash Flow From Operations | 8.67 M | ||||
| Earnings Per Share | 0.08 X | ||||
| Total Asset | 73.42 M | ||||
| Retained Earnings | (378.39 M) | ||||
| Current Asset | 59.65 M | ||||
| Current Liabilities | 10.33 M | ||||
About Protalix Biotherapeutics Performance
Evaluating Protalix Biotherapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Protalix Biotherapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Protalix Biotherapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company was founded in 1993 and is based in Hackensack, New Jersey. Protalix Biotherapeutics operates under Biotechnology classification in the United States and is traded on AMEX Exchange. It employs 202 people.Things to note about Protalix Biotherapeutics performance evaluation
Checking the ongoing alerts about Protalix Biotherapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Protalix Biotherapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Protalix Biotherapeutics generated a negative expected return over the last 90 days | |
| Protalix Biotherapeutics may become a speculative penny stock | |
| Protalix Biotherapeutics has high historical volatility and very poor performance |
- Analyzing Protalix Biotherapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Protalix Biotherapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Protalix Biotherapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Protalix Biotherapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Protalix Biotherapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Protalix Biotherapeutics' stock. These opinions can provide insight into Protalix Biotherapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Protalix Stock Analysis
When running Protalix Biotherapeutics' price analysis, check to measure Protalix Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protalix Biotherapeutics is operating at the current time. Most of Protalix Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Protalix Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protalix Biotherapeutics' price. Additionally, you may evaluate how the addition of Protalix Biotherapeutics to your portfolios can decrease your overall portfolio volatility.